Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids

What this Trial Is About

Researchers are studying glucocorticoid-induced osteoporosis (GIOP) in patients with chronic inflammatory rheumatic diseases or psoriasis. Glucocorticoids are commonly used to treat these conditions but can cause unwanted side effects, especially when used at higher doses for long periods. The study aims to collect and analyze detailed disease- and bone-related data to better understand the frequency and severity of GIOP, an area where current knowledge and scientific data are limited or outdated. This observational trial involves patients with or without chronic inflammatory rheumatic diseases or psoriasis who may have received or are expected to receive glucocorticoid therapy. Participants attend outpatient clinics for diagnosis, treatment, or follow-up of osteoporosis and bone metabolism according to current guidelines. Data from more than 1000 patients will be documented prospectively over the first three years, including those treated with glucocorticoids and control groups without such treatment. Participants will undergo clinical, laboratory, and instrumental examinations to collect information on bone mineral density and glucocorticoid usage, including dosage and duration. Researchers will monitor these outcomes over periods ranging from days to years. The study collects data from routine consultations and referrals, focusing on osteoporosis diagnosis, treatment, and follow-up. Participation involves consenting to data collection and storage, with ongoing assessment throughout the study period.

Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis